Nevro Corp Stock Performance
| NVRO Stock | USD 4.55 0.03 0.66% |
The company secures a Beta (Market Risk) of 2.33, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Nevro Corp will likely underperform. At this point, Nevro Corp has a negative expected return of -0.25%. Please make sure to verify Nevro Corp's value at risk and rate of daily change , to decide if Nevro Corp performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Nevro Corp has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Actual Historical Performance (%)
One Day Return 4.65 | Five Day Return 12.35 | Year To Date Return (77.22) | Ten Year Return (82.81) | All Time Return (81.22) |
Last Split Factor 1:24 | Last Split Date 2014-11-06 |
1 | Disposition of 1020 shares by D Grossman of Nevro Corp at 5.55 subject to Rule 16b-3 | 09/03/2024 |
2 | Disposition of 1759 shares by Kashif Rashid of Nevro Corp at 5.18 subject to Rule 16b-3 | 09/06/2024 |
3 | Disposition of 3070 shares by Greg Siller of Nevro Corp at 5.85 subject to Rule 16b-3 | 09/19/2024 |
4 | Why Nevro Stands Out as a Strong Growth Candidate | 09/26/2024 |
5 | Disposition of 479 shares by Kashif Rashid of Nevro Corp at 4.97 subject to Rule 16b-3 | 10/04/2024 |
6 | Acquisition by Michael DeMane of 4695 shares of Nevro Corp subject to Rule 16b-3 | 10/11/2024 |
7 | Disposition of 6063 shares by Kevin Thornal of Nevro Corp at 4.85 subject to Rule 16b-3 | 10/24/2024 |
8 | DarioHealth Corp. Reports Q3 Loss, Tops Revenue Estimates | 11/07/2024 |
9 | Nevro Reports Third-Quarter 2024 Financial Results | 11/11/2024 |
10 | Nevros HFX iQ Spinal Cord Stimulation with AI Technology Receives CE Mark Certification in Europe, Increasing Product Expansion Globally | 11/12/2024 |
11 | Robert W. Baird Issues Positive Forecast for Nevro Stock Price | 11/13/2024 |
12 | Analysts Are Updating Their Nevro Corp. Estimates After Its Third-Quarter Results | 11/14/2024 |
13 | New Study Demonstrates Multiple Advantages of Nevro1, the Novel | 11/18/2024 |
14 | Nevros SI joint fixation system delivers enhanced stability and fusion for patients | 11/19/2024 |
| Begin Period Cash Flow | 121 M | |
| Free Cash Flow | -67.4 M |
Nevro |
Nevro Corp Relative Risk vs. Return Landscape
If you would invest 576.00 in Nevro Corp on August 28, 2024 and sell it today you would lose (121.00) from holding Nevro Corp or give up 21.01% of portfolio value over 90 days. Nevro Corp is currently does not generate positive expected returns and assumes 5.0209% risk (volatility on return distribution) over the 90 days horizon. In different words, 44% of stocks are less volatile than Nevro, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Nevro Corp Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Nevro Corp's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Nevro Corp, and traders can use it to determine the average amount a Nevro Corp's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0499
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | NVRO |
Estimated Market Risk
| 5.02 actual daily | 44 56% of assets are more volatile |
Expected Return
| -0.25 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Nevro Corp is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Nevro Corp by adding Nevro Corp to a well-diversified portfolio.
Nevro Corp Fundamentals Growth
Nevro Stock prices reflect investors' perceptions of the future prospects and financial health of Nevro Corp, and Nevro Corp fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Nevro Stock performance.
| Return On Equity | -0.25 | ||||
| Return On Asset | -0.0902 | ||||
| Profit Margin | (0.17) % | ||||
| Operating Margin | (0.16) % | ||||
| Current Valuation | 138.92 M | ||||
| Shares Outstanding | 37.47 M | ||||
| Price To Earning | (63.38) X | ||||
| Price To Book | 0.62 X | ||||
| Price To Sales | 0.40 X | ||||
| Revenue | 425.17 M | ||||
| Gross Profit | 276.37 M | ||||
| EBITDA | (78.31 M) | ||||
| Net Income | (92.21 M) | ||||
| Cash And Equivalents | 310.82 M | ||||
| Cash Per Share | 8.78 X | ||||
| Total Debt | 221.83 M | ||||
| Debt To Equity | 0.89 % | ||||
| Current Ratio | 6.65 X | ||||
| Book Value Per Share | 7.31 X | ||||
| Cash Flow From Operations | (58.83 M) | ||||
| Earnings Per Share | (1.87) X | ||||
| Market Capitalization | 169.37 M | ||||
| Total Asset | 635.71 M | ||||
| Retained Earnings | (699.41 M) | ||||
| Working Capital | 447.55 M | ||||
| Current Asset | 282.63 M | ||||
| Current Liabilities | 36.39 M | ||||
About Nevro Corp Performance
By examining Nevro Corp's fundamental ratios, stakeholders can obtain critical insights into Nevro Corp's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Nevro Corp is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 320.59 | 425.62 | |
| Return On Tangible Assets | (0.16) | (0.17) | |
| Return On Capital Employed | (0.18) | (0.19) | |
| Return On Assets | (0.15) | (0.15) | |
| Return On Equity | (0.31) | (0.33) |
Things to note about Nevro Corp performance evaluation
Checking the ongoing alerts about Nevro Corp for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Nevro Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Nevro Corp generated a negative expected return over the last 90 days | |
| Nevro Corp has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 425.17 M. Net Loss for the year was (92.21 M) with profit before overhead, payroll, taxes, and interest of 276.37 M. | |
| Nevro Corp currently holds about 310.82 M in cash with (58.83 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.78, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Nevro Corp has a poor financial position based on the latest SEC disclosures | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from massdevice.com: Nevros SI joint fixation system delivers enhanced stability and fusion for patients |
- Analyzing Nevro Corp's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Nevro Corp's stock is overvalued or undervalued compared to its peers.
- Examining Nevro Corp's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Nevro Corp's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Nevro Corp's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Nevro Corp's stock. These opinions can provide insight into Nevro Corp's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nevro Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Nevro Stock, please use our How to Invest in Nevro Corp guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nevro Corp. If investors know Nevro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nevro Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.87) | Revenue Per Share 11.404 | Quarterly Revenue Growth (0.07) | Return On Assets (0.09) | Return On Equity (0.25) |
The market value of Nevro Corp is measured differently than its book value, which is the value of Nevro that is recorded on the company's balance sheet. Investors also form their own opinion of Nevro Corp's value that differs from its market value or its book value, called intrinsic value, which is Nevro Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nevro Corp's market value can be influenced by many factors that don't directly affect Nevro Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nevro Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Nevro Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nevro Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.